פוסרנול     750 מג טבליות לעיסה ישראל - עברית - Ministry of Health

פוסרנול 750 מג טבליות לעיסה

takeda israel ltd - lanthanum as carbonate hydrate - טבליות לעיסות - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

פוסרנול  1000 מג בליות לעיסה ישראל - עברית - Ministry of Health

פוסרנול 1000 מג בליות לעיסה

takeda israel ltd - lanthanum as carbonate hydrate - טבליות לעיסות - lanthanum as carbonate hydrate 1000 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

סודיום יודיד (T-131 ) כמוסות T ישראל - עברית - Ministry of Health

סודיום יודיד (t-131 ) כמוסות t

isorad ltd, israel - iodine sodium - קפסולות - iodine sodium 37 mbq - sodium iodide (131i) - sodium iodide (131i) - treatment of graves disease, toxic multinodular goite or autonomous nodules. treatment of papillary and follicular thyroid carcinoma including metastatic disease. sodium iodide (i-131) therapy is often combined with surgical intervention and with antithyroid medications.

טי.אר.ה. ישראל - עברית - Ministry of Health

טי.אר.ה.

ferring pharmaceuticals ltd - protirelin 0.2 mg/ml - solution for injection - tests for thyreoidea function - for monitoring the functional state of the hypothalamo- pituitary-thyroid axis.

פוסרנול 1000 מג אבקה למתן דרך הפה ישראל - עברית - Ministry of Health

פוסרנול 1000 מג אבקה למתן דרך הפה

takeda israel ltd - lanthanum as carbonate hydrate - אבקה - lanthanum as carbonate hydrate 1000 mg - lanthanum carbonate

פוסרנול 750 מג אבקה למתן דרך הפה ישראל - עברית - Ministry of Health

פוסרנול 750 מג אבקה למתן דרך הפה

takeda israel ltd - lanthanum as carbonate hydrate - אבקה - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate

פרבליפ 10 ישראל - עברית - Ministry of Health

פרבליפ 10

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin

טורבה 10 ישראל - עברית - Ministry of Health

טורבה 10

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - טבליה - atorvastatin as calcium trihydrate salt 10 mg - atorvastatin - atorvastatin - torid is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torid is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/

טורבה 20 ישראל - עברית - Ministry of Health

טורבה 20

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - טבליה - atorvastatin as calcium trihydrate salt 20 mg - atorvastatin - atorvastatin - torid is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torid is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/

טורבה 40 ישראל - עברית - Ministry of Health

טורבה 40

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - טבליה - atorvastatin as calcium trihydrate salt 40 mg - atorvastatin - atorvastatin - torid is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torid is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/